No Data
No Data
NextCure Shares Are Trading Lower. The Company Announced Results From Its Phase 1b Study of NC410.
NextCure Presented Results of the Phase 1b Study of NC410 in Combination With Pembrolizumab at ESMO 2024
Express News | NextCure Presented Results of the Phase 1B Study of Nc410 in Combination With Pembrolizumab at Esmo 2024
Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?
NextCure Price Target Maintained With a $4.00/Share by Needham
Piper Sandler Maintains NextCure(NXTC.US) With Buy Rating, Maintains Target Price $3
Piper Sandler analyst Edward Tenthoff maintains $NextCure(NXTC.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 35.8% and a